While other pharma companies are entering Singapore, owing to its far-sightedness, Merck is expanding by establishing a new manufacturing facility. By investing $500 million, Merck’s new establishment now contains a vial-packaging department to churn out cancer treatment Keytruda as well as a three-syringe packaging sector to formulate Merck’s HPV vaccine Gardasil. The facility also has cold storage and a new quality control laboratory. Other than establishing the new locations, Merck has allocated some funds for projects that will concentrate on the company’s environmental sustainability goals and improving information technology. The new funds will produce 100 employment roles.
Read More from FiercePharma
English